

## TABLE OF CONTENTS

### **CHAPTER 1. INTRODUCTION**

<b>1.1 Introduction to TB pathology.....</b>	<b>1</b>
1.1.1 Development for TB diagnosis, vaccine and treatment.....	1
1.1.2 Global TB status-2019.....	2
1.1.3 TB Regulations.....	2
1.1.4 Why is TB drug development important?.....	3
1.1.5 Future Prospects.....	3
1.1.6 Classification of TB Drug.....	3
<b>1.2 Impurity profiling.....</b>	<b>4</b>
1.2.1 Definitions and synonyms.....	4
1.2.2 Regulatory requirements for impurity study.....	5
1.2.3 Sources of impurity.....	6
1.2.4 Approach to impurity profiling.....	9
1.2.5 Control of impurity.....	14
1.2.6 Degradation kinetic study of API.....	16
1.2.7 Kinetic parameters.....	17
<b>1.3 Design of Experiments (DoE).....</b>	<b>19</b>
1.3.1 Design of Experiments steps .....	20
1.3.2 Experimental Designs.....	21
References.....	23

### **CHAPTER 2. AIMS AND OBJECTIVES.....29**

### **CHAPTER 3. STRESS DEGRADATION STUDY AND IMPURITY PROFILING OF TERIZIDONE**

3.1 Selection of drug.....	31
3.2 Drug Profile.....	32
3.3 Literature review.....	33

3.4 Bulk Drug Identification.....	33
-----------------------------------	----

### **3.5 Part- A**

Development and validation of stability indicating HPLC method and stress degradation study of Terizidone

3.5.1 Experimental.....	37
-------------------------	----

3.5.2 Results and Discussion.....	42
-----------------------------------	----

3.5.2.1 Determination of Suitable wavelength.....	42
---	----

3.5.2.2 Method development and optimization .....	42
---	----

3.5.2.3 Stress degradation studies.....	43
---	----

3.5.2.4 Validation of stability indicating method.....	54
--	----

3.5.2.5 Application of developed stability indicating assay method for analysis of formulation.....	58
---	----

3.5.2.6 Comparison with reported stability indicating method.....	59
---	----

### **3.6 Part-B**

Degradation kinetic study of Terizidone

3.6.1 Experimental.....	60
-------------------------	----

3.6.2. Results and Discussion.....	61
------------------------------------	----

3.6.2.1 Acid degradation kinetic.....	61
---------------------------------------	----

3.6.2.2 Alkali degradation kinetic.....	68
---	----

3.6.2.3 Neutral degradation kinetics .....	73
--	----

3.6.2.4 Oxidative degradation kinetics.....	77
---	----

### **3.7 Part- C**

Isolation and characterization of major degradation products of Terizidone

3.7.1 Experimental.....	83
-------------------------	----

3.7.2 Results and Discussion.....	85
-----------------------------------	----

3.7.2.1 Spectral analysis of TRZ bulk drug.....	85
---	----

3.7.2.2 Acid degradation impurity (DP-A4).....	87
--	----

3.7.2.3 Neutral degradation impurity (DP-N3).....	94
---	----

3.7.2.4 Oxidative degradation impurity (DP-O7).....	102
---	-----

### **3.8 Part- D**

Impurity profiling of Terizidone

3.8.1 Experimental.....	111
-------------------------	-----

3.8.2 Results and discussion.....	111
-----------------------------------	-----

3.8.2.1 Analysis of TRZ bulk drug and process related impurity.....	112
---	-----

3.8.2.2 Acid degraded impurity.....	115
-------------------------------------	-----

3.8.2.3 Neutral degraded impurity.....	126
--	-----

3.8.2.4 TRZ in alkaline medium.....	132
-------------------------------------	-----

3.8.2.4 TRZ in oxidative medium.....	132
--------------------------------------	-----

References.....	138
-----------------	-----

## **CHAPTER 4. STRESS DEGRADATION STUDY AND IMPURITY PROFILING OF BEDAQUILINE**

4.1 Selection of drug.....	140
----------------------------	-----

4.2 Drug profile.....	141
-----------------------	-----

4.3 Literature review.....	142
----------------------------	-----

4.4 Drug identification.....	142
------------------------------	-----

### **4.5 Part- A**

Development and validation of stability indicating HPLC method and stress degradation study of bedaquiline

4.5.1 Experimental.....	146
-------------------------	-----

4.5.2 Results and Discussion.....	151
-----------------------------------	-----

4.5.2.1 Determination of suitable wavelength.....	151
---	-----

4.5.2.2 Method development and optimization.....	151
--	-----

4.5.2.3 Stress degradation study .....	152
--	-----

4.5.2.4 Validation of stability indicating method.....	160
--	-----

4.5.2.5 Applicability of developed stability indicating assay method for analysis of formulation.(Synthetic mixture).....	164
---	-----

## **4.6 Part- B**

Degradation kinetic study of Bedaquiline

4.6.1 Experimental.....	166
4.6.2 Result and Discussion.....	167
4.6.2.1 Hydrolytic degradation kinetic study.....	167
4.6.2.2 Oxidative degradation kinetic study.....	179

## **4.7 Part-C**

Multi-factorial design tool for degradation kinetics study of bedaquiline

4.7.1 Experimental.....	185
4.7.2 Result and discussion .....	186
4.7.2.1 Hydrolytic degradation kinetic.....	186
4.6.2.2 Oxidative degradation kinetic.....	200
Conclusion .....	207

## **4.8 Part- D**

Isolation and characterization of major DPs of bedaquiline

4.8.1 Experimental.....	208
4.8.2 Result and Discussion.....	210
4.8.2.1 Spectral analysis of BDQ.....	210
4.8.2.2 Acid degradation impurity.....	214
4.8.2.3 Oxidative degradation impurity.....	222

## **4.9 Part- E**

Impurity profiling of bedaquiline

4.9.1 Experimental.....	231
4.9.2 Result and Discussion.....	231
4.9.2.1 Process related impurity.....	232
4.9.2.2 Acid degradation impurity.....	235
4.9.2.3 Oxidation of BDQ.....	245
Conclusion.....	252

References.....	254
-----------------	-----

## **CHAPTER 5. STRESS DEGRADATION STUDY AND IMPURITY PROFILING OF RIFABUTIN**

5.1 Selection of drug.....	256
----------------------------	-----

5.2 Literature Review.....	257
----------------------------	-----

5.3 Drug Profile.....	258
-----------------------	-----

5.4 Bulk drug identification.....	259
-----------------------------------	-----

### **5.5 Part- A**

Development and validation of stability indicating method and stress degradation study of rifabutin

5.5.1 Experimental.....	263
-------------------------	-----

5.5.2 Results and Discussion.....	266
-----------------------------------	-----

5.5.2.1 Determination of suitable wavelength .....	266
--	-----

5.5.2.2 Method development and optimization .....	266
---	-----

5.5.2.3 Stress degradation study.....	267
---------------------------------------	-----

5.5.2.4 validation of stability indicating method .....	275
---	-----

5.5.2.5 Applicability of developed stability indicating assay method for analysis of formulation.....	279
---	-----

### **5.6 Part- B**

Degradation kinetic study of Rifabutin by HPLC method

5.6.1 Experimental.....	281
-------------------------	-----

5.6.2 Result and Discussion.....	282
----------------------------------	-----

5.6.2.1 Acid degradation kinetic study.....	282
---	-----

5.6.2.2 Alkaline degradation kinetic study .....	287
--	-----

5.6.2.2 Peroxide induced degradation kinetic.....	290
---	-----

### **5.7 Part- C**

Multi-factorial design tool for degradation kinetics of rifabutin

5.7.1 Experimental.....	297
-------------------------	-----

5.7.2 Result and discussion .....	298
5.7.2.1 Hydrolytic degradation kinetic.....	299
5.7.2.2 Oxidative degradation kinetic.....	311
<b>5.8 Part- D</b>	
Isolation and characterization of major DPs of Rifabutin	
5.8.1 Experimental.....	319
5.8.2 Result and Discussion.....	320
5.8.2.1 Alkali degradation impurity.....	320
5.8.2.2 Acid degradation impurity.....	331
<b>5.9 Part- E</b>	
Impurity profiling of Rifabutin	
5.9.1 Experimental.....	338
5.9.2 Result and Discussion.....	338
5.9.2.1 Analysis of rifabutin.....	338
5.9.2.2 Alkali degradation impurity.....	343
5.9.2.3 Acid degradation impurity.....	350
5.9.2.4 Oxidative degradation impurity.....	360
Conclusion.....	363
References.....	364
<b>CHAPTER-6 REVIEW AND SUMMARY OF THE STUDY.....</b>	<b>367</b>
<b>APPENDIX I</b>	
<b>APPENDIX II</b>	